Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280522030> ?p ?o ?g. }
- W4280522030 endingPage "973" @default.
- W4280522030 startingPage "965" @default.
- W4280522030 abstract "Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable glucokinase activator that enhances glucokinase activity in a glucose-dependent manner, improves glucose-stimulated insulin secretion and demonstrates effects on glycemic control in patients with T2D. We report the findings of a randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the efficacy and safety of dorzagliatin in patients with T2D. Eligible drug-naïve patients with T2D (n = 463) were randomly assigned to the dorzagliatin or placebo group at a ratio of 2:1 for 24 weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin from baseline to week 24. Safety was assessed throughout the trial. At week 24, the least-squares mean change in glycated hemoglobin from baseline (95% confidence interval) was -1.07% (-1.19%, -0.95%) in the dorzagliatin group and -0.50% (-0.68%, -0.32%) in the placebo group (estimated treatment difference, -0.57%; 95% confidence interval: -0.79%, -0.36%; P < 0.001). The incidence of adverse events was similar between the two groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin group. In summary, dorzagliatin improved glycemic control in drug-naïve patients with T2D and showed a good tolerability and safety profile." @default.
- W4280522030 created "2022-05-22" @default.
- W4280522030 creator A5000159943 @default.
- W4280522030 creator A5000561844 @default.
- W4280522030 creator A5000919346 @default.
- W4280522030 creator A5006595708 @default.
- W4280522030 creator A5012578672 @default.
- W4280522030 creator A5014109910 @default.
- W4280522030 creator A5014201221 @default.
- W4280522030 creator A5014510012 @default.
- W4280522030 creator A5014686788 @default.
- W4280522030 creator A5017610735 @default.
- W4280522030 creator A5019056174 @default.
- W4280522030 creator A5020014720 @default.
- W4280522030 creator A5021589498 @default.
- W4280522030 creator A5024807781 @default.
- W4280522030 creator A5027310979 @default.
- W4280522030 creator A5029875458 @default.
- W4280522030 creator A5031646804 @default.
- W4280522030 creator A5033889854 @default.
- W4280522030 creator A5033983569 @default.
- W4280522030 creator A5036245477 @default.
- W4280522030 creator A5037731533 @default.
- W4280522030 creator A5038327368 @default.
- W4280522030 creator A5044544424 @default.
- W4280522030 creator A5045779549 @default.
- W4280522030 creator A5046074895 @default.
- W4280522030 creator A5049586655 @default.
- W4280522030 creator A5049638501 @default.
- W4280522030 creator A5049949859 @default.
- W4280522030 creator A5051862250 @default.
- W4280522030 creator A5052191175 @default.
- W4280522030 creator A5055165930 @default.
- W4280522030 creator A5056145672 @default.
- W4280522030 creator A5058417870 @default.
- W4280522030 creator A5058736223 @default.
- W4280522030 creator A5066470511 @default.
- W4280522030 creator A5070820936 @default.
- W4280522030 creator A5073070877 @default.
- W4280522030 creator A5076752869 @default.
- W4280522030 creator A5077624156 @default.
- W4280522030 creator A5080888480 @default.
- W4280522030 creator A5081066035 @default.
- W4280522030 creator A5083527446 @default.
- W4280522030 creator A5083821650 @default.
- W4280522030 creator A5083822183 @default.
- W4280522030 creator A5084345156 @default.
- W4280522030 creator A5088598702 @default.
- W4280522030 date "2022-05-01" @default.
- W4280522030 modified "2023-10-17" @default.
- W4280522030 title "Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial" @default.
- W4280522030 cites W1573318520 @default.
- W4280522030 cites W1972051717 @default.
- W4280522030 cites W1973268992 @default.
- W4280522030 cites W1975535652 @default.
- W4280522030 cites W1982600501 @default.
- W4280522030 cites W1992428632 @default.
- W4280522030 cites W2005561360 @default.
- W4280522030 cites W2014190569 @default.
- W4280522030 cites W2020214777 @default.
- W4280522030 cites W2026640914 @default.
- W4280522030 cites W2027862526 @default.
- W4280522030 cites W2030386197 @default.
- W4280522030 cites W2031134755 @default.
- W4280522030 cites W2033125833 @default.
- W4280522030 cites W2049016439 @default.
- W4280522030 cites W2050605495 @default.
- W4280522030 cites W2084447305 @default.
- W4280522030 cites W2103348177 @default.
- W4280522030 cites W2107568971 @default.
- W4280522030 cites W2112941360 @default.
- W4280522030 cites W2134056179 @default.
- W4280522030 cites W2140979674 @default.
- W4280522030 cites W2146118393 @default.
- W4280522030 cites W2153041556 @default.
- W4280522030 cites W2154118045 @default.
- W4280522030 cites W2159859567 @default.
- W4280522030 cites W2160873546 @default.
- W4280522030 cites W2161641259 @default.
- W4280522030 cites W2164306929 @default.
- W4280522030 cites W2176469395 @default.
- W4280522030 cites W2269288506 @default.
- W4280522030 cites W2296239131 @default.
- W4280522030 cites W2330339020 @default.
- W4280522030 cites W2345694792 @default.
- W4280522030 cites W2412167093 @default.
- W4280522030 cites W2471356895 @default.
- W4280522030 cites W2579141064 @default.
- W4280522030 cites W2731349674 @default.
- W4280522030 cites W2786903684 @default.
- W4280522030 cites W2799564070 @default.
- W4280522030 cites W2801191096 @default.
- W4280522030 cites W2801193581 @default.
- W4280522030 cites W2909977372 @default.
- W4280522030 cites W2921967571 @default.
- W4280522030 cites W2948869937 @default.
- W4280522030 cites W3096753335 @default.
- W4280522030 cites W3105119519 @default.